Moolec Science SA
LUXEMBOURG / ACCESSWIRE / July 15, 2024 / Moolec Science SA (NASDAQ:MLEC) ("the Company"), a Molecular Farming ingredient company, announced today the signing of an offtake agreement with one of the largest global consumer packaged goods and pet food companies for the use of Moolec's patented science-based GLA Safflower Oil product, GLASO™ (the "Agreement"). This initial offtake agreement has a term of three years and establishes commercial conditions for the delivery of GLASO™ in US territory with an initial estimated volume of 50 tons for 2025.
To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.
GLASO™ is a nutritional omega 6 oil obtained from bioengineered safflower seeds. With high-GLA (gamma linolenic acid) concentration, Moolec's product contains almost 3 times more GLA than conventional sources such as borage and primrose oil, making it the most concentrated GLA oil available on the market. GLA is widely recognized for its health-promoting attributes and is primarily embraced as a valuable addition to various diets in the form of a dietary supplement, functional food, cosmetics, and animal nutrition such as pet food, main application targeted by this offtake Agreement.
Moolec Science also announces that it has signed binding agreements with farmers to cultivate safflower as well as with an industrial partner to secure state of the art downstream capacity. Both agreements are paramount to ensure a fully-controlled and traceable supply chain for GLASO™.
"We are thrilled to announce this significant supply agreement for our GLASO™ nutritional oil product. This milestone, coupled with our new partnership for industrial toll processing, marks a pivotal step in our mission to deliver high-quality, innovative health solutions to our customers worldwide. It underscores our commitment to quickly scaling from small to large volume production and meeting the growing demand for sustainable nutritional ingredients," said Martín Salinas, Chief Technology Officer & Co-Founder of the Company.
Moolec's Molecular Farming Platform encompasses revolutionary technology enabling the production of high-quality ingredients, such as nutritional oils and proteins, in plants. The company leads the industry in demonstrating that its technology can be scaled efficiently, affordably, and sustainably. This allows for ingredients to be designed that will offer significant cost-in-use reductions compared to traditional and cellular agricultural methods.
Gastón Paladini, CEO & Co-Founder of Moolec, concluded: "We are very excited about this team accomplishment. It is a concrete and important step in Moolec's path to commercialize our flagship technology. Going forward, we will intensify our business development and commercialization efforts with major participants in the manufacturing and ingredients business."
Note to reader: Due to the competitive nature of these agreements, and the fact that Moolec Science is in continuing negotiations for further contracts, disclosure over third parties and price will not be made at this time. Moolec Science will keep the market informed with updates on its annual report that provides a comprehensive overview of the company's business and financial condition.
Forward-Looking Statements
This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.
Contact Information
Press & Media
comms@moolecscience.com
Investor Relations
ir@moolecscience.com
Related Files
SOURCE: Moolec Science
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Cleverbridge Appoints Markus Scheuermann as Chief Financial Officer12.2.2025 05:00:00 CET | Press release
Seasoned Finance Leader Brings 20+ Years of Expertise in Financial Strategy, M&A and Digital Transformation to Cleverbridge COLOGNE, GERMANY & CHICAGO, IL / ACCESS Newswire / February 12, 2025 / Cleverbridge, a leading provider of ecommerce and billing solutions for global software and SaaS companies, today announced the appointment of Markus Scheuermann as Chief Financial Officer, effective as of April 1, 2025.Markus Scheuermann Scheuermann is a seasoned senior executive with over 20 years of experience in financial strategy, business development, M&A, and digital transformation within high-performing technology organizations. Most recently, he served as Chief Financial Officer at Thinkproject Group and has previously held key leadership roles at HolidayCheck Group, Hubert Burda Media, eBay, and McKinsey & Company. Markus will report directly to Wendi Sturgis, Cleverbridge CEO, and be part of an executive leadership team that includes CRO Kevin Feagan, CTO Radu Immenroth, and CHRO Ale
CGFNS International Reports Nurse Migration Rates to the U.S. Remained High in 202411.2.2025 11:45:00 CET | Press release
Uncertain outlook for 2025 as new immigration policies are implemented PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / February 11, 2025 / A new CGFNS International report indicates that a robust annual rate of nurse migration into the United States held steady in 2024 as healthcare systems continued to look to foreign-educated nurses to help address persistent staffing shortages.CGFNS International 2024 Nurse Migration Report However, in its 2024 Nurse Migration Report, the organization also said the current high rates were likely unsustainable amid persisting visa retrogression and caps on employment-based green cards for nurses, along with new immigration policies being implemented by the Trump Administration that will likely have further impact on visa availability and processing times. CGFNS, a global health workforce non-profit that verifies credentials of healthcare professionals for immigration authorities and state licensing boards, reported that in fiscal year 2024 it received
An Incredible KLAS Triple-Award Win for AGFA HealthCare!10.2.2025 09:00:00 CET | Press release
MORTSEL, BE / ACCESS Newswire / February 10, 2025 / AGFA HealthCare proudly celebrates a remarkable KLAS triple-win, securing two #1 Best in KLAS Awards for XERO® Viewer and VNA, alongside the KLAS Most Improved Software Product for 2025. "To receive a KLAS Award is one of the most notable wins for AGFA HealthCare, and a testament to the hard work we invest into our flagship platform. More importantly, it reflects the trust and recognition from our customers. Their success is our success, and to receive two such awards is simply breathtaking." - Nathalie McCaughley, President, AGFA HealthCare The Best in KLAS report recognizes software and service providers who excel in supporting healthcare professionals and patient care. Based on extensive customer feedback and evaluations, these awards highlight AGFA HealthCare's unwavering commitment to innovation and excellence. For 2025, AGFA HealthCare's Enterprise Imaging XERO® Viewer leads the Universal Viewer (Imaging) category for the second
Eviva Partners, a New Nonprofit Promoting Better Understanding of Medical Evidence, Exposes Role of Andrew Wakefield in the “Manufacture of Evidence” Leading Up to Robert F. Kennedy Jr’s Confirmation Hearings10.2.2025 07:50:00 CET | Press release
Introduces the concept of "Evidence Fluency" as a solution to the current crisis and a path towards improving healthcare overall NEW YORK CITY, NEW YORK / ACCESS Newswire / February 10, 2025 / Eviva Partners, a pioneering healthcare initiative founded by physician-scientist Alex Morozov, announced its launch today with an innovative mission to address critical gaps in healthcare delivery through "evidence fluency" - a new framework for understanding and communicating medical evidence. "The new US Administration is poised to have a dramatic impact on the integrity of scientific publications and medical evidence," said Alex Morozov, CEO and Founder. "An investigation over the past several days reveals a role of Andrew Wakefield in the "Manufacture of Evidence" leading up to Robert F. Kennedy Jr's Confirmation hearings. Wakefield 30 years ago was paid by another anti-vaccine lawyer, Richard Barr, to manufacture a study through research fraud showing a link between vaccines and autism. His
Registration Now Open for World of Coffee 2025 in Geneva: The Premier Event for Coffee Professionals6.2.2025 09:00:00 CET | Press release
Join Over 13,000 Attendees and 430+ Exhibitors at Europe's Largest Specialty Coffee Trade Show GENEVA, SWITZERLAND / ACCESS Newswire / February 6, 2025 / World of Coffee, the essential event for coffee professionals, enthusiasts, and innovators from around the globe will have a 2025 edition in Geneva, Switzerland, at the Palexpo SA, June 26-28. Following the record-breaking success of World of Coffee in Copenhagen, this flagship coffee trade show is set to welcome over 13,000 coffee professionals from 160+ countries for three days of business, networking, and education. Produced by the Specialty Coffee Association (SCA), the trade show and conference are proudly supported by Host Sponsor BTW Water + More; Platinum Sponsor Barista Attitude; Diamond Sponsor Nestlé Professional; and Gold Sponsor Alpro. Café de Colombia will be featured as the Portrait Country with unique cultural activations, and a pop-up café experience. "Geneva is the ideal location for hosting our flagship European tra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom